Kratom science has matured dramatically. More than two hundred relevant studies have been published since 2018, supported in large part by the National Institute on Drug Abuse — the lead federal agency for kratom research — which supports work both on kratom's health effects and on potential medicinal uses of its compounds.
A federal milestone: kratom's primary compound enters human trials
On June 1, 2026, the National Institutes of Health announced that its Investigational New Drug application for mitragynine — kratom's primary active compound — is in effect with the FDA, clearing the way for an NIH-led Phase I clinical trial evaluating mitragynine as a potential treatment for opioid use disorder. The purified formulation was developed by researchers at NIH and the University of Florida, after preclinical studies across multiple doses raised no significant safety concerns in animal models. NIH scientists plan the first randomized, double-blind, placebo-controlled human study of the compound, conducted under the NIH HEAL Initiative. NIDA Director Nora Volkow called the milestone a major step toward expanding treatment options for the millions of Americans struggling with opioid use disorder.
The significance is hard to overstate: the same federal government that once proposed banning kratom's compounds is now advancing one of them into human trials as a possible answer to the deadliest drug crisis in American history.
The comprehensive safety picture
The most complete recent synthesis — a 2024 review in Frontiers in Pharmacology drawing on several hundred papers across pharmacology, toxicology, and epidemiology — reached conclusions that should anchor any policy discussion: kratom use in the U.S. involves millions of adults and is no longer niche; kratom's pharmacology is diverse and complex rather than simply opioid-like; serious adverse events are low relative to comparable substances; and the evidence base is now sufficient to support what the authors recommend — federal regulatory standards for purity, labeling, and marketing through the FDA. Science, in other words, points to the same destination as the KCPA: regulate, don't ban.
This page is updated as significant research is published. Direct links to the primary sources are below.
Sources
- NIH/NIDA news release, June 1, 2026: NIH research clears way for study of experimental treatment for opioid use disorder.
- NIDA. Kratom research topic: nida.nih.gov/research-topics/kratom.
- Henningfield JE, Grundmann O, Huestis MA, Smith KE. Kratom safety and toxicology in the public health context: research needs to better inform regulation. Frontiers in Pharmacology 15 (2024): DOI 10.3389/fphar.2024.1403140.